Glycosaminoglycans in autoimmunity

Clinical and Experimental Rheumatology

Volumn 14, Issue SUPPL. 15, 1996, Pages

  Hansen, Ch ^a   Otto, E ^a   Kuhlemann, K ^a   Forster G ^a   Kahaly, G J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

autoimmune diseases; glycosaminoglycans

Indexed keywords

GLYCOSAMINOGLYCAN;

AUTOIMMUNITY; CONFERENCE PAPER; DIAGNOSIS; ETIOLOGY; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE;

ANIMALS; ANTIBODY FORMATION; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GLYCOSAMINOGLYCANS; HUMANS; IMMUNITY, CELLULAR; THYROID GLAND;

EID: 0029740026     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. WIGHT TN, HEINEGARD DK, HASCALL VC: Proteoglycans, structure and function. In HAY ED (Ed.): Cell Biology of Extracellular Matrix, 2nd ed., New York, Plenum Press, 1991: 45-78.
2. POULSEN JH: Urine and tissue glycosaminoglycans and their interrelations. Dan Med Bull 1986; 33: 75-96.
3. ARUFFO A, STAMENKOVIC I, MELNICK M, UNDERHILL CB, SEED B: CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-13.
4. UNDERHILL CB: Naturally-occurring antibodies which bind hyaluronate. Biochem Biophys Res Commun 1982; 108: 1488-94.
5. FILLIT HM, BLAKE M, MCDONALD C, MCCARTHY M: Immunogenicity of liposome-bound hyaluronate in mice. J Exp Med 1988; 168: 971-82.
6. WOLF H, WICK G: Antibodies interacting with, and corresponding binding site for, heparin on human thrombocytes. Lancet 1986; ii: 222-3.
7. HIRSH J: Drug therapy: Heparin. N Engl J Med 1991; 324: 1565-74.
8. FAABER P, CAPEL PJA, RIJKE GPM, VIERWINDEN G, VAN DE PUTTE LBA, KOENE RAP: Cross-reactivity of anti-DNA antibodies with proteoglycans. Clin Exp Immunol 1984; 55: 502-8.
9. FAABER P, RIJKE PM, VAN DE PUTTE LBA, CAPEL PJA, BERDEN JHM: Cross-reactivity of human and murine anti-DNA antibodies with heparan sulphate. The major glycosaminoglycan in glomerular basement membrane. J Clin Invest 1986; 77: 1824.
10. SHIBATA S, HARPEL P, BONA C, FILLIT H: Monoclonal antibodies to heparan sulphate inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 1993; 67: 264-72.
11. KAHALY G, HANSEN C, STOVER C, BEYER J, OTTO E: Glycosaminoglycan antibodies in endocrine ophthalmopathy. Horm Metab Res 1993; 25: 637-9.
12. KAHALY G, HANSEN C, STOVER C, KUHLEMANN K, BEYER J, OTTO E: Glycosaminoglycans and endocrine orbitopathy. Exp Clin Endocrinol 1994; 102: 151-61.
13. WINAND RJ, WADELEUX PA: Glycosaminoglycans and orbital connective tissue autoantibodies. Acta Endocrinol 1989, 121: 51-5.
14. TSAO M, FERRARINI M, EVANS C, AMBRO A, WHITESIDE TL: Purification of a glycosaminoglycan-stimulatory lymphokine from supernatants of in vitro-activated human mono-nuclear cells. Clin Immunol Immunopathol 1989; 50: 122-31.
15. KAHALY G, STOVER C, OTTO E, BEYER J, SCHULER M: Glycosaminoglycans in thyroid-associated ophthalmopathy. Autoimmunity 1992; 13: 81-8.
16. DUNCAN MR, WILSON TJ, VAN DE WATER J, BERMAN B, BOYD R, WICK G, GERSHWIN ME: Cultured fibroblasts in avian scleroderma, an autoimmune fibrotic disease, display an activated phenotype. J Autoimmun 1992; 5: 603-15.
17. SHIMIZU Y, VAN SEVENTER GA, SIRAGANIAN R, WAHL L, SHAW S: Dual role of the CD44 molecule in cell adhesion and activation. J Immunol 1989; 143: 2457-63.
18. HUET S, GROUX H. CAILLOU B, VALENTIN H, PRIEUR A, BERNARD A: CD44 contributes to T cell activation. J Immunol 1989; 143: 798-801.
19. KOOPMAN G, VAN KOOYK, DE GRAEFF M, MEYER CJLM, FIGDOR CG, PALS ST: Triggering of CD44 antigen on thymocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 1990; 145: 3589-93.
20. CONRAD P, ROTHMANN BL, KELLY KA, BLUE ML: Mechanism of peripheral T cell activation by coengagement of CD44 and CD2. J Immunol 1992; 149: 1830-3.
21. WEETMAN AP, MCGREGOR AM: Autoimmune thyroid disease: Further developments in our understanding. Endocr Rev 1994; 15: 788-830.
22. BURCH HB, WARTOFSKY L: Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747-93.
23. CAMPBELL RJ: Immunology of Graves' ophthalmopathy: Retrobulbar histology and histochemistry. Acta Endocrinol 1989; 121 (Suppl. 2): 9-16.
24. WEETMAN AP, COHEN S, GATTER KC, FELLS P, SHINE B: Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989;75:222-7.
25. SMITH TJ, BAHN RS, GORMAN CA: Connective tissue, glycosaminoglycans, and disease of the thyroid. Endocr Rev 1989; 10: 366-91.
26. SCHULER M, HANSEN C, WINAND R, STOVER C, OTTO E, BEYER J, KAHALY G: Urinary and plasma glycosaminoglycans in endocrine ophthalmopathy. In KAHALY G (Ed.): Endocrine Ophthalmopathy. Molecular, Immunological and Clinical Aspects. Basel, Karger, 1993; 25: 58-67.
27. KAHALY G, HANSEN C, FELKE B, DIENES HP: Immuno-histochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol 1994; 73: 53-62.
28. KAHALY G, SCHULER M, SEWELL AC, BERNHARD G, BEYER J, KRAUSE U: Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin Endocrinol 1990; 33: 35-44.
29. KAHALY G, HANSEN C, BEYER J, WINAND R: Plasma glycosaminoglycans in endocrine ophthalmopathy. J Endocrinol Invest 1994; 17: 45-50.
30. CHANG TC, YAO WC, CHANG CC: Octreotide and urinary glycosaminoglycan in Graves' disease. Br Med J 1992; 304: 1444.
31. HANSEN C, FRAITURE B, ROUHI R, KUHLEMANN K, OTTO E, BEYER J, KAHALY G: New HPLC method to analyse the aberrant distribution of glycosaminoglycan in Graves' ophthalmopathy. Thyroid 1995; 5 (Suppl. 1): S185.
32. SCHLEICHER E, NERLICH A, GERBITZ KD: Pathobiochemical aspects of diabetic nephropathy. Klin Wschr 1988; 66: 873-82.
33. PFEIFFER A, SCHATZ H: Diabetic microvascular complications and growth factors. Exp Clin Endocrinol 1995; 103: 7-14.
34. WASTY F, ALAVI MZ, MOORE S: Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993; 36:316-22.
35. HEICKENDORFF L, LEDET T, RASMUSSEN LM: Glycosaminoglycans in the human aorta in diabetes mellitus : a study of tunica media from areas with and without atherosclerotic plaque. Diabetologia 1994; 37: 286-92.
36. SIVALINGAM A, KENNEY J, BROWN GC, BENSON WE, DONOSO L: Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 869-72.
37. DECKERT T, KOFOED-ENEVOLDSEN A, VIDAL P, NORGAARD K, ANDREASEN HB, FELDT-RASMUSSEN B: Size- and charge selectivity of glomerular filtration in Type I (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993; 36: 244-51.
38. MORAN A, BROWN DM, KIM Y, KLEIN DJ: Effects of IGF-1 and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture. Diabetes 1991; 40: 1346-54.
39. SHIMOMURA H, SPIRO RG: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulphate proteoglycan and laminin. Diabetes 1987; 36: 347-81.
40. TAMSMA JT, VANDEN BORN J, BRUIJN JA, ASSMANN KJM, WEENING JJ, BERDEN JHM, WIESLANDER J, SCHRAMA E, HERMANS J, VEERKAMP JH, LEMKES HHPJ, VAN DER WOUDE FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37: 313-20.
41. HANSEN C, IRMSCHER A-K, KUHLEMANN K, BEYER J, KAHALY G: Insulin-dependent diabetes mellitus and glycosaminoglycans. Horm Metab Res 1995; 27: 555-8.